SHJ 002
Alternative Names: Anti-myopia eyedrop - Sun Hawk Vision Biotech; microRNA-328 antisense oligonucleotide - Sunhawk Vision Biotech; miRNA-328 antisense oligonucleotide -… See moreLatest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Sunhawk Vision Biotech
- Class Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Corneal disorders; Dry eyes; Myopia
Most Recent Events
- 07 Jan 2025 Phase-II clinical trials in Myopia (In children) in Taiwan (Ophthalmic) (NCT06579287)
- 07 Jan 2025 Phase-II clinical trials in Myopia (In children) in USA (Ophthalmic) (NCT06579287)
- 30 Aug 2024 Sunhawk Vision Biotech plans a phase II trial for Myopia (Children) in USA (Opthalmic) (NCT06579287)